These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18056407)

  • 1. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
    Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
    J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
    Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
    J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation.
    Chung I; Leonhardt H; Rippe K
    J Cell Sci; 2011 Nov; 124(Pt 21):3603-18. PubMed ID: 22045732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.
    Jiang WQ; Zhong ZH; Henson JD; Reddel RR
    Oncogene; 2007 Jul; 26(32):4635-47. PubMed ID: 17297460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
    Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
    Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
    Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
    Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
    Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins.
    Jiang WQ; Zhong ZH; Nguyen A; Henson JD; Toouli CD; Braithwaite AW; Reddel RR
    J Cell Biol; 2009 Jun; 185(5):797-810. PubMed ID: 19468068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
    Shen H; Maki CG
    J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence.
    Fujita K; Horikawa I; Mondal AM; Jenkins LM; Appella E; Vojtesek B; Bourdon JC; Lane DP; Harris CC
    Nat Cell Biol; 2010 Dec; 12(12):1205-12. PubMed ID: 21057505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
    Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
    Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.
    Yu J; Lan J; Wang C; Wu Q; Zhu Y; Lai X; Sun J; Jin C; Huang H
    Cancer Lett; 2010 May; 291(2):177-86. PubMed ID: 19900757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
    Grobelny JV; Godwin AK; Broccoli D
    J Cell Sci; 2000 Dec; 113 Pt 24():4577-85. PubMed ID: 11082050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
    Temime-Smaali N; Guittat L; Wenner T; Bayart E; Douarre C; Gomez D; Giraud-Panis MJ; Londono-Vallejo A; Gilson E; Amor-Guéret M; Riou JF
    EMBO J; 2008 May; 27(10):1513-24. PubMed ID: 18418389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 governs telomere regulation feedback too, via TRF2.
    Horikawa I; Fujita K; Harris CC
    Aging (Albany NY); 2011 Jan; 3(1):26-32. PubMed ID: 21266744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRF2 dysfunction elicits DNA damage responses associated with senescence in proliferating neural cells and differentiation of neurons.
    Zhang P; Furukawa K; Opresko PL; Xu X; Bohr VA; Mattson MP
    J Neurochem; 2006 Apr; 97(2):567-81. PubMed ID: 16539655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shelterin protein TRF2 inhibits Chk2 activity at telomeres in the absence of DNA damage.
    Buscemi G; Zannini L; Fontanella E; Lecis D; Lisanti S; Delia D
    Curr Biol; 2009 May; 19(10):874-9. PubMed ID: 19375317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
    Peche LY; Scolz M; Ladelfa MF; Monte M; Schneider C
    Cell Death Differ; 2012 Jun; 19(6):926-36. PubMed ID: 22117195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines.
    French JD; Dunn J; Smart CE; Manning N; Brown MA
    Genes Chromosomes Cancer; 2006 Mar; 45(3):277-89. PubMed ID: 16283620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1.
    Denchi EL; de Lange T
    Nature; 2007 Aug; 448(7157):1068-71. PubMed ID: 17687332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.